Clinical trial

Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates

NCT01484080

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention BIBF + Paclitaxel Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Paclitaxel Normalized identity: paclitaxelView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2011-10-01

PhasePHASE1 / PHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

BIBF + PaclitaxelDRUG

PaclitaxelDRUG · verified · RxNorm: paclitaxel

Sponsors & collaborators

Centro Nacional de Investigaciones Oncologicas CARLOS IIIlead sponsor

Hospital Universitario de Fuenlabradacollaborator

M.D. Anderson Cancer Centercollaborator

Hospital Universitari de Bellvitgecollaborator

Grupo Espanol de Investigacion del Cancer de Mamacollaborator

Mapped research locations

MadridSpain1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01484080 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.